- •Preface
- •Contents
- •Contributors
- •1.1 Introduction
- •1.2 Pathogenesis of AMD
- •1.2.1 Oxidative Damage
- •1.2.2 Lipofuscin Accumulation
- •1.2.4 Complement Mutations
- •1.2.5 Mitochondrial Damage
- •1.2.6 DICER 1
- •1.3 Treatment
- •1.3.1 Antioxidants
- •1.3.2 Visual Cycle Modulators
- •1.3.4 Neurotrophic Agents
- •1.3.5 Antiangiogenic Agents
- •1.3.5.1 Intracellular Angiogenic Factor Production
- •1.3.5.2 Extracellular Angiogenic Factors
- •1.3.6 Endothelial Cell Receptor Binding
- •1.3.7 Endothelial Cell Activation
- •1.3.8 Endothelial Cell Proliferation
- •1.3.9 Endothelial Cell Directional Migration
- •1.3.10 Extracellular Matrix Remodeling
- •1.3.11 Tube Formation
- •1.3.11.1 Loop Formation (Arteriovenous Differentiation)
- •1.3.11.2 Vascular Stabilization
- •1.4 Combination Therapy
- •1.5 Conclusions
- •References
- •2.1 Introduction
- •2.1.1 Complement Pathways
- •2.1.2 Oxidative Stress
- •2.3.1 The Mouse CNV Model
- •2.3.2 RPE Monolayers
- •2.3.3 Concept
- •2.5 Summary and Outlook
- •References
- •3.1 Introduction
- •3.2.1 Advanced Glycation End Products
- •3.2.2 Carboxyethylpyrrole
- •3.2.3 Oxidation Products of Lipofuscin
- •3.3 Summary and Conclusions
- •References
- •4.1 Introduction
- •4.2 Oxidative Stress and AMD
- •4.2.1 Basic Concepts on Oxidative Stress
- •4.2.2 Oxidative Stress in AMD
- •4.3 Malondialdehyde in AMD
- •4.3.1 Lipid Peroxidation and Malondialdehyde
- •4.3.2 Materials and Methods
- •4.3.2.1 RPE Cell Culture
- •4.3.2.2 Patients
- •4.3.2.3 MDA Assay
- •4.3.3 MDA Levels in Cultured RPE Cells and in Patients with AMD
- •4.4 Summary and Conclusions
- •References
- •5.1 Introduction
- •5.2 The Origin and Housing of RPE Lipofuscin
- •5.3 Bisretinoid Constituents of RPE Lipofuscin
- •5.3.1 A2E, Isomers and Precursors
- •5.3.4 Photooxidized Forms of Bisretinoid Pigments
- •5.4 Photoreactivity of RPE Lipofuscin
- •5.5 Photooxidation of RPE Bisretinoids
- •5.6 Bisretinoid Photodegradation
- •5.7 Potential for Cell and Tissue Damage
- •5.9 A Role for Antioxidants
- •5.10 Conclusions
- •References
- •6.1 Introduction
- •6.1.1 RPE Lipofuscin Accumulation with Age and Relation to AMD
- •6.1.2 Known Chromophores Found in RPE Lipofuscin and the Mechanism of Damage
- •6.1.3 Formation of Higher Molecular Weight Material
- •6.1.4 Current Studies and Possible Structures of Higher Molecular Weight Products
- •6.1.4.1 Lipofuscin Extracts
- •6.1.4.3 Esters and Aldehydes
- •6.2 Conclusions
- •References
- •7.2 DHA in Photoreceptor Cells
- •7.3 Neuroprotectin D1 Synthesis is an Early Response to Oxidative Stress in RPE Cells
- •7.5 Neurotrophins Trigger the Synthesis and Polarized Secretion of Neuroprotectin D1 from Human RPE Cells
- •7.6 Photoreceptor Outer Segment Phagocytosis Induces RPE Cell Survival Signaling with Associated Synthesis of NPD1 During Oxidative Stress
- •References
- •8.1 Introduction
- •8.2.1 Subcellular Localization
- •8.2.2 Expression Levels in the Retina
- •8.4.3 Regulation of RDH12 Expression and Activity During Chronic and Acute Stress
- •8.5 RDH12 and Leber Congenital Amaurosis
- •8.5.1 Inactivating Mutations of RDH12
- •8.5.2 Loss of Which RDH12 Function Induces LCA?
- •8.6 Summary and Conclusions
- •References
- •9.1 Introduction
- •9.2 GSH Metabolism: General Principles
- •9.2.2 Role of Mitochondrial GSH in Protection
- •9.2.3 GSH as a ROS Scavenger
- •9.2.4 GSH Distribution in the Retina and RPE in Health and Disease
- •9.5 Future Perspectives
- •References
- •10.1 Introduction
- •10.2 Mitochondria
- •10.2.1 Mitochondrial Biogenesis and Maintenance
- •10.2.2 Mitochondrial Removal and Degradation
- •10.3 Mitochondria and Reactive Oxygen Species
- •10.3.1 Reactive Oxygen and Nitrogen Species (ROS and RNS)
- •10.3.2 Mitochondria are a Major Source of Intracellular ROS
- •10.3.3 Other Sources of ROS in the Retina
- •10.4 The Mitochondrial Genome
- •10.4.1 Susceptibility of Mitochondrial DNA to Oxidative Stress
- •10.4.2 Mitochondrial DNA Damage
- •10.4.3 Mitochondrial DNA Repair Pathways
- •10.4.4 The Mitochondrial Base Excision Repair (mtBER) Pathway
- •10.4.6 Other Mitochondrial DNA Repair Pathways
- •10.4.6.2 Mismatch Repair (MMR)
- •10.4.6.3 Translesion Synthesis (TLS) and Damage Tolerance
- •10.4.6.4 Nucleotide Excision Repair (NER)
- •10.4.7 Intramitochondrial Localization of DNA Repair Proteins
- •10.4.8 mtDNA Damage Sensing and Signaling
- •10.4.9 Import of Nuclear Encoded DNA Repair Enzymes into the Mitochondria
- •10.5 Mitochondrial DNA Damage/Repair in the Retina and RPE
- •10.5.1 Mitochondrial DNA Damage/Repair in the RPE
- •10.5.2 DNA Repair and the Adaptive Response in the RPE
- •10.6 Pathologies Associated with Mitochondrial Dysfunction and Oxidative Stress in the Retina
- •10.6.2 Diabetic Retinopathy
- •10.6.3 Glaucoma
- •10.6.4 Uveitis
- •10.7 Pathologies Associated with Inherited Mitochondrial Disorders
- •10.8 Potential Therapeutic Options for Targeting Mitochondrial DNA Damage
- •10.8.1 Mitochondrial Biogenesis
- •10.8.2 Enhancing mtDNA Repair
- •10.8.3 Antioxidants
- •10.8.4 Autophagy
- •10.9 Conclusion
- •References
- •11.1 Introduction
- •11.2 ER Function in Normal Physiology
- •11.2.1 Major Roles of Rough ER (RER) and Smooth ER (SER)
- •11.2.2 ER and Oxidative Protein Folding
- •11.2.3 ER Resident Proteins
- •11.2.4 Potential Threat to ER Function in RPE
- •11.3 ER Response to Oxidative Stress in RPE
- •11.3.2 Initiation of UPR to Alleviate ER Burden
- •11.4 Chronic ER Stress and Oxidative Stress in the Vicious Cycle of Apoptosis Induction
- •11.5 Future Perspectives
- •References
- •12.1 Introduction
- •12.2 Iron Homeostasis
- •12.2.1 General Iron Homeostasis
- •12.2.2 Iron Import into the Retina
- •12.2.2.1 Transferrin Mediated Transport
- •12.2.2.3 Dexras
- •12.2.3 Iron Storage
- •12.2.3.1 Ferritin
- •12.2.3.2 Mitochondrial Ferritin
- •12.2.4 Iron Export
- •12.2.4.1 Ceruloplasmin
- •12.2.4.2 Hephaestin
- •12.2.4.3 Ferroportin and Hepcidin
- •12.3 Disruption of Iron Homeostasis and Oxidative Damage
- •12.4 Retinal Disorders Resulting from Abnormal Retinal Iron Metabolism
- •12.4.2 Aceruloplasminemia
- •12.4.3 Hemochromatosis
- •12.4.4 Friedreich’s Ataxia
- •12.4.6 Siderosis
- •12.4.7 Subretinal Hemorrhage
- •12.5 Potential Therapeutics
- •References
- •13.1 Vascular Endothelial Growth Factor and Its Functions in the Retina
- •13.1.1 VEGF Isoforms
- •13.1.2 VEGF Functions
- •13.1.3 Cells Secreting VEGF in the Retina
- •13.1.3.1 Retinal Pigment Epithelium
- •13.1.3.2 Müller Cells
- •13.1.3.3 Astrocytes
- •13.1.3.4 Pericytes
- •13.1.4 VEGF Receptors and VEGF Induced Signal Transduction
- •13.1.4.1 VEGF Receptors
- •VEGFR-1
- •VEGFR-2
- •Neuropilin
- •Heparan Sulfate Proteoglycan
- •13.2 Regulation of VEGF Expression
- •13.2.1 Transcriptional Regulation
- •13.2.2 Translational Regulation
- •13.2.3 Hypoxia Induced VEGF Regulation
- •13.2.4 Posttranslational Regulation
- •13.2.5 Autocrine VEGF Regulation
- •13.2.6 Pathological VEGF Production
- •13.2.6.1 Hyperglycemia
- •13.2.6.2 Oxidative Stress
- •13.2.6.3 Cytokines
- •13.2.6.4 Endoplasmic Reticulum
- •13.2.6.5 Additional Factors
- •13.3.1 Pegaptanib
- •13.3.2 Bevacizumab and Ranibizumab
- •13.3.4 siRNA
- •13.3.5 Small Molecule Tryrosine Kinase Inhibitors
- •13.3.6 Other Inhibitors
- •13.4.2 Interaction of VEGF Antagonists with Antiangiogenic VEGFxxxb
- •13.5 Conclusion
- •References
- •14.1 Introduction
- •14.2 NADPH Oxidase and Redox Signaling
- •14.3 Expression of NADPH Oxidase Subunit p22phox in the Retina
- •14.4 NADPH Oxidase and Choroidal Neovascularization
- •14.5 Implication and Therapeutic Potential of NADPH Oxidase in Development of CNV
- •14.6 Summary and Future Perspective
- •References
- •15.1 Introduction
- •15.2 Aging
- •15.3 Deposition and Formation of Oxidized LDL
- •15.6 Treatments for AMD
- •15.7 Conclusions
- •References
- •16.1 Introduction
- •16.2 HGF and Its Receptor (MET)
- •16.2.1 Production and Secretion of HGF
- •16.2.2 MET and Biological Effects of HGF
- •16.2.3 Signaling Pathways of HGF
- •16.2.4 HGF and MET in Disease States
- •16.4 HGF Protects RPE Cells from Oxidative Stress
- •16.4.1 HGF and RPE Cells
- •16.4.2 HGF Promotes Cell Survival
- •16.4.3 HGF Protects Cells from Oxidative Stress
- •16.4.4 HGF Protects RPE Cells from Hydrogen Peroxide
- •16.4.5 HGF Protects RPE Cells Against Ceramide Damage
- •16.4.6 HGF Protects RPE Cells from Glutathione Depletion
- •References
- •17.1 Introduction
- •17.2.1 Fundoscopy
- •17.2.2 Histology
- •17.2.3 Ultrastructure
- •17.3.1 Lipofuscin (A2E)
- •17.3.3 HtrA2/Omi
- •References
- •18.1 Introduction
- •18.2 Systemic Markers of Oxidative Stress
- •18.2.1 Redox Status
- •18.2.2 DNA Damage
- •18.2.4 Lipid Peroxidation
- •18.3 Defenses Against Oxidative Stress
- •18.3.1 Antioxidants
- •18.3.2 Antioxidant Enzymes
- •18.4 Oxidative Stress and Genetics
- •18.4.1 Antioxidant Enzyme Polymorphisms
- •18.5 Environmental Exposures and Oxidative Stress
- •18.5.1 Smoking
- •18.5.2 Light Exposure
- •18.6 AMD Treatments and Oxidative Stress
- •18.8 Summary and Conclusions
- •References
- •19.1 Characteristics of Cerium Oxide Nanoparticles
- •19.3 Mechanism of Nanoceria Uptake, Internalization, and Localization in the Cell
- •19.4 Biological Effect, Functional Mechanism, and Applications
- •19.4.1 Bacteria
- •19.4.2 Plants
- •19.4.3 Medical Usage
- •19.4.3.1 Radioprotectants
- •19.4.3.2 Burn Treatment
- •19.4.4 Medical Imaging
- •19.5 Stability of Nanoceria Under storage Conditions and Its Longevity in the Cell In Vivo
- •19.6 Oxidative Damage Results in Neurodegeneration
- •19.7.1 Prolong Cellular Life Span
- •19.7.2 Cardioprotection
- •19.8 Treatment of Ocular Disorders
- •19.8.1 Methodology
- •19.8.2 Prevention of Light Damage and Rescue of Retinal Function
- •19.8.3 Treatment of Degenerative Ocular Diseases
- •19.8.4 Treatment of Ocular Neovascular Diseases
- •19.9 Toxicity and Environmental Impacts
- •19.10 Conclusion and Future Directions
- •References
- •20.1 Introduction
- •20.2 Retinal Progenitor Cells (RPCs) Are Multipotential
- •20.4 Therapeutic Strategies for Repair and Regeneration of Retinal Cells: Repair of the RPE
- •20.5 Challenges for RPE Stem Cell Therapy
- •20.6 Characterization of RPE-Like Cells Derived from BMDCs
- •20.7 BMDCs Differentiate into Retinal Cells
- •20.8 Summary and Future of Cell Therapy for Dysfunctional RPE
- •References
- •21.1 Introduction
- •21.2 Carotenoids in Retinal Diseases
- •21.4 Polyphenols or Phenolic Esters in Retinopathies
- •21.4.1 Caffeic Acid Phenethyl Ester
- •21.4.2 Catechin
- •21.4.3 Curcumin
- •21.4.4 Proanthocyanidin
- •21.4.5 Resveratrol
- •21.5.2 Sulforaphane
- •21.6 Vitamins in Retinopathies
- •21.6.1 Vitamin A
- •21.7 Perspectives
- •References
- •22.1 Introduction
- •22.1.1 Neuroprotection as a Strategy for Retinal Degenerative Disease
- •22.2.2 Putative Mechanisms of CNS Neuroprotection
- •22.3.9 Conclusion
- •22.4 Mechanisms of Retinal Protection
- •22.4.1 Insights from In Vitro Models
- •22.5.1 Background to the Disease and the Associated Preclinical Data
- •22.5.2 Overview of the Clinical Development Program
- •References
- •23.1 Introduction
- •23.2 Pathogenesis
- •23.4 Pegaptanib
- •23.5 Bevacizumab
- •23.6 Ranibizumab
- •23.7.1 Ranibizumab
- •23.7.2 Bevacizumab
- •23.8 Comparison of AMD Treatment Trials (CATT)
- •23.9 Management of Nonresponders
- •23.11 Conclusion
- •References
- •24.1 Introduction
- •24.2 Rationale for Combination Therapy
- •24.3 Supporting Evidence for Combination Therapy
- •24.4 Currently Applied Combination Therapies
- •24.5 Challenges for Combination Therapy
- •References
- •25.1 Human Endothelial Progenitor Cells
- •25.3 Function of EPCs
- •25.3.1 EPCs in Vascular Repair and Neovascularization
- •25.4 EPCs in Diabetes
- •25.4.1 EPC as a Biomarker in Diabetes
- •25.4.1.1 EPC Dysfunction in Diabetes
- •25.4.1.2 Oxidative Stress and EPC Dysfunction in Diabetes
- •25.4.1.3 Therapeutic Angiogenesis by EPCs in Diabetic Retinopathy
- •25.5 Conclusion
- •References
- •26.1 Introduction
- •26.1.1 Nitric Oxide
- •26.1.2 Nitric Oxide Regulation
- •26.1.3 Nitric Oxide in Normal and Pathophysiological Conditions
- •26.2 Retinal Vascular Diseases: The Role of iNOS
- •26.2.1 Nitric Oxide in Diabetic Retinopathy
- •26.2.2 iNOS in Diabetic Retinopathy
- •26.2.2.2 iNOS and Leukocyte Adhesion to Retinal Vessels
- •26.2.2.3 iNOS and Retinal Cell Death
- •26.2.3 Proliferative Retinal Diseases
- •26.2.3.1 iNOS and Proliferative Retinal Diseases
- •26.2.3.2 iNOS and Ocular Neovascularization in Retinal Vascular Diseases
- •26.3 Conclusions
- •References
- •27.1 Introduction
- •27.2 Animal Model
- •27.2.1 LHP Preparation and Injection Procedure
- •27.2.2 Acridine Orange Digital Fluorography
- •27.3 Experimental Results
- •27.3.1 Leukocyte Rolling
- •27.3.2 Accumulated Leukocytes in the Retinal Microcirculation
- •27.3.3 Diameter of Major Retinal Vessels
- •27.3.4 SOD Treatment
- •27.4 Discussion
- •27.5 Conclusions
- •References
- •28.1 Introduction
- •28.1.2 Metabolism and Balance in Generation and Quenching of ROS
- •28.2 Role of Oxygen Concentration on Generation of ROS in the Developing Retina
- •28.3.1 Perinatal Considerations
- •28.3.2 Neonatal Considerations
- •28.3.2.1 Polyunsaturated Fatty Acids in Retina and Brain
- •28.3.2.2 Increased Oxidation
- •28.3.2.3 Reduced Antioxidant Enzyme Systems
- •28.3.3 Environmental Stimuli
- •28.3.3.1 Light
- •28.3.3.2 Oxygen Changes in Development and Prematurity
- •28.3.3.3 Nutrition
- •28.3.3.4 Effect of Blood Transfusions on Oxidative Stress in Prematurity
- •28.4 Evidence from Animal Models
- •28.4.1 Background
- •28.4.2 Effects of Hypoxia on Bioenergetic Oxygen Sensor Mechanisms and Related to ROP
- •28.4.2.2 NADPH Oxidase
- •28.4.2.3 Cytochrome p450 Monooxygenases (CYP)
- •28.4.2.4 eNOS
- •28.4.2.5 Heme Oxygenase
- •28.4.2.6 Metabolic Effects of Hypoxia
- •28.4.3 Laboratory Evidence of Antioxidants on Animal Models of ROP
- •28.5 Clinical Studies of Antioxidants on ROP
- •28.6 Genetics
- •28.7 Summary
- •References
- •29.1 Introduction
- •29.1.1 Oxidative Stress in Glaucoma
- •29.1.2 Oxidative Stress in Diabetic Retinopathy
- •29.1.3 Oxidative Stress in Age Related Macular Degeneration
- •29.1.4 Vascular Endothelial Growth Factor
- •29.1.5 VEGF Mediated Neuroprotection
- •29.1.6 Mechanisms of VEGF Protection Against Oxidative Stress
- •References
- •30.1 Introduction
- •30.1.1 Oxidation and Oxidative Stress
- •30.1.2 Reactive Oxygen Intermediates
- •30.1.3 ROIs and Cellular Retinal Damage
- •30.1.4 Light, Cellular Retinal Damage and AMD
- •30.1.5 Carotenoids
- •30.1.6 Chemistry of Carotenoids: Basic Structural Components
- •30.2 Building Blocks
- •30.3 The Polyene Backbone
- •30.5 Terminal Groups
- •30.5.1 Source of Macular Carotenoids
- •30.5.2 Macular Carotenoids: The Origins of Macular Pigment
- •30.5.3 The Functions of the Macular Carotenoids as Macular Pigment for AMD
- •30.6 Antioxidant Properties
- •30.6.1 The Functions of the Macular Carotenoids as Macular Pigment for Visual Performance
- •References
- •31.1 Introduction
- •31.2 Composition and Distribution
- •31.3 Selective Uptake and Deposition Process of MP
- •31.4 Measurements
- •31.4.1 Heterochromatic Flicker Photometry
- •31.4.4 Resonance Raman Spectroscopy
- •31.5 Antioxidant Mechanism of MP and Its Relation to Retinal Health and Disease
- •31.5.1 Oxidative Stress in Human Retina and the Antioxidant Mechanism of MP
- •31.5.2 MP in Human Eye Health and Disease
- •31.5.2.2 MacTel
- •31.5.2.3 Acuity
- •31.6 Ocular Carotenoid Supplementation Studies
- •31.7 Conclusion
- •References
- •Index
- •About the Authors
Contributors
António F. Ambrósio Centre of Ophthalmology and Vision Sciences, Institute of Biomedical Research in Light and Image (IBILI), Faculty of Medicine, University of Coimbra, Coimbra, Portugal
Bela Anand-Apte Department of Ophthalmology,
Cole Eye Institute, Cleveland Clinic Lerner College of Medicine at Case Western Reserve University, Cleveland, OH, USA
Robert E. Anderson Departments of Ophthalmology
and Cell Biology, Oklahoma City, OK, USA
McGee Eye Institute, Oklahoma City, OK, USA
Donald Armstrong Department of Ophthalmology, University of Florida, College of Medicine, Gainesville, FL, USA
John D. Ash Department of Ophthalmology, Oklahoma University Health Sciences Center, Oklahoma City, OK, USA
Albert J. Augustin Department of Ophthalmology, Klinikum Karlsruhe,
Karlsruhe, Germany
Mausumi Bandyopadhyay Department of Ophthalmology, Medical University of South Carolina, Charleston, SC, USA
Nicolas G. Bazan Neuroscience Center of Excellence
and Department of Ophthalmology, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, USA
Paul S. Bernstein Department of Ophthalmology and Visual Sciences, University of Utah, Moran Eye Center, Salt Lake City, UT, USA
Michael E. Boulton Department of Anatomy and Cell Biology, College of Medicine, University of Florida, Gainesville, FL, USA
xi
xii |
Contributors |
Milam A. Brantley Jr. Vanderbilt Eye Institute, Vanderbilt University, Nashville, TN, USA
Vikram S. Brar Department of Ophthalmology, University of Florida, College of Medicine, Jacksonville, FL, USA
Jiyang Cai Vanderbilt Eye Institute, Vanderbilt University, Nashville, TN, USA
Xue Cai Department of Ophthalmology, Dean McGee Eye Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
K.V. Chalam Department of Ophthalmology, University of Florida, College of Medicine, Jacksonville, FL, USA
Robert Collier Retina Research Alcon Laboratories, Inc.,
Fort Worth, TX, USA
John W. Crabb Departments of Ophthalmology and Molecular Medicine, Cole Eye Institute and Lerner Research Institute, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA
José Cunha-Vaz Department of Ophthalmology, Faculty of Medicine, University of Coimbra, Association for Innovation and Biomedical Research on Light and Image (AIBILI), Azinhaga Santa Comba, Coimbra, Portugal
Margaret M. DeAngelis Department of Ophthalmology, University of Utah, Salt Lake City, UT, USA
A.E. Dill GreatPoint Energy, Chicago, IL, USA
J. Dillon Department of Chemistry and Biochemistry, Northern Illinois University, Dekalb, IL, USA
Department of Ophthalmology, Columbia University, New York, NY, USA
Astra Dinculescu Department of Ophthalmology, University of Florida, College of Medicine, Gainesville, FL, USA
Guorui Dou Department of Ophthalmology, Xijing Hospital, Fourth Military Medical University, XiÕan, Shaanxi, China
Joshua L. Dunaief F. M. Kirby Center for Molecular Ophthalmology, University of Pennsylvania, Philadelphia, PA, USA
Harry W. Flynn Jr. Bascom Palmer Eye Institute, University of Miami, Miller School of Medicine, Miami, FL, USA
E.R. Gaillard Department of Chemistry and Biochemistry, Northern Illinois University, Dekalb, IL, USA
Department of Ophthalmology, Columbia University, New York, NY, USA
Thomas W. Gardner Ophthalmology and Visual Sciences and Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI, USA
Contributors xiii
Maria B. Grant Department of Pharmacology and Therapeutics, University of Florida, Gainesville, FL, USA
Anasheh Halabi Neuroscience Center of Excellence and Department
of Ophthalmology, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, USA
Jeffrey R. Harris Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC, USA
Mary Elizabeth Hartnett Departments of Ophthalmology and Pediatrics, Moran Eye Center, University of Utah, Salt Lake City, UT, USA
William W. Hauswirth Department of Ophthalmology, University of Florida, College of Medicine, Gainesville, FL, USA
Yu-Guang He Department of Ophthalmology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA
David R. Hinton Arnold and Mabel Beckman Macular Research Center, Doheny Eye Institute, Departments of Pathology and Ophthalmology, Keck School of Medicine of the University of Southern California,
Los Angeles, CA, USA
Dan-Ning Hu Tissue Culture Center, The New York Eye and Ear InÞrmary, New York, NY, USA
Department of Ophthalmology, New York Medical College, New York, NY, USA
Stuart G. Jarrett Department of Molecular and Biomedical Pharmacology, College of Medicine, University of Kentucky, Lexington, KY, USA
John M. Johnston Department of Ophthalmology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA
Ram Kannan Arnold and Mabel Beckman Macular Research Center, Doheny Eye Institute, Department of Ophthalmology, Keck School of Medicine
of the University of Southern California, Los Angeles, CA, USA
Anne Kasus-Jacobi Department of Ophthalmology, Oklahoma University Health Sciences Center, Oklahoma City, OK, USA
Alexa Klettner Department of Ophthalmology, University of Kiel, University Medical Center, Kiel, Germany
Jaclyn L. Kovach Department of Clinical Ophthalmology, University of Miami, Miller School of Medicine, Bascom Palmer Eye Institute, Miami, FL, USA
Kannan Kunchithapautham Department of Ophthalmology, Medical University of South Carolina, Charleston, SC, USA
Ermelindo C. Leal Centre of Ophthalmology and Vision Sciences
Institute of Biomedical Research in Light and Image (IBILI), Faculty of Medicine, University of Coimbra, Coimbra, Portugal
xiv |
Contributors |
Alfred S. Lewin Department of Molecular Genetics and Microbiology, University of Florida, College of Medicine, Gainesville, FL, USA
Binxing Li Department of Ophthalmology and Visual Sciences, University of Utah, Moran Eye Center, School of Medicine, Salt Lake City, UT, USA
Qiuhong Li Department of Ophthalmology, University of Florida, College of Medicine, Gainesville, FL, USA
Nawajes A. Mandal Department of Ophthalmology, Oklahoma City, OK, USA
McGee Eye Institute, Oklahoma City, OK, USA
Akihisa Matsubara Department of Ophthalmology and Visual Science, Nagoya City University, Graduate School of Medical, Nagoya, Japan
Yoshito Matsuda Department of Ophthalmology and Visual Science, Nagoya City University Medical School, Nagoya, Japan
Steven A. McCormick Department of Pathology and Laboratory Medicine, The New York Eye and Ear InÞrmary, New York, NY, USA
Department of Pathology, Ophthalmology and Otolaryngology, New York Medical College, New York, NY, USA
James F. McGinnis Department of Ophthalmology, Dean McGee Eye Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
Neuroscience Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
Sonia Mehta Duke Eye Center, Duke University School of Medicine, Durham, NC, USA
Hiroshi Morita Department of Ophthalmology and Visual Science, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan
L.S. Murdaugh Department of Chemistry and Biochemistry, Northern Illinois University, Dekalb, IL, USA
Matthew B. Neu Department of Pharmacology and Therapeutics, University of Florida, Gainesville, FL, USA
Thierry N. Ngansop Department of Ophthalmology, Oklahoma University Health Sciences Center, Oklahoma City, OK, USA
John M. Nolan Macular Pigment Research Group, Carriganore House, Waterford Institute of Technology, West Campus, Waterford, Ireland
Glenn Noronha Retina Research Alcon Laboratories, Inc.,
Fort Worth, TX, USA
Contributors |
xv |
Yuichiro Ogura Department of Ophthalmology and Visual Science, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan
Melissa P. Osborn Vanderbilt Eye Institute, Vanderbilt University, Nashville, TN, USA
Joan E. Roberts Department of Chemistry, Division of Natural Sciences, Fordham University, New York, NY, USA
Ignacio R. Rodriguez Laboratory of Retinal Cell and Molecular Biology, National Eye Institute, Bethesda, MD, USA
Bärbel Rohrer Department of Ophthalmology, Medical University of South Carolina, Charleston, SC, USA
Johann Roider Department of Ophthalmology, University of Kiel, University Medical Center, Kiel, Germany
Carmelo Romano Retina Research Alcon Laboratories, Inc., Fort Worth, TX, USA
Richard Rosen Department of Ophthalmology, Ophthalmology Research,
New York Eye and Ear InÞrmary, New York Medical College, New York, NY, USA
Philip J. Rosenfeld Bascom Palmer Eye Institute,
University of Miami, Miller School of Medicine, Miami, FL, USA
Anisse Saadi Department of Ophthalmology, Oklahoma University Health Sciences Center, Oklahoma City, OK, USA
Stefan Scholl Department of Ophthalmology, Klinikum Karlsruhe, Karlsruhe,
Germany
Retina Research Institute, Baden-Baden, Germany
Stephen G. Schwartz Bascom Palmer Eye Institute,
University of Miami, Miller School of Medicine, Miami, FL, USA
Ingrid U. Scott Bascom Palmer Eye Institute, University of Miami, Miller School of Medicine, Miami, FL, USA
Penn State University, Penn State Hershey Eye Center, Hershey, PA, USA
Sudipta Seal Advanced Materials Processing Analysis Center, Nanoscience Technology Center, Mechanical Materials Aerospace Eng, University of Central Florida, Orlando, FL, USA
J.D. Simon Department of Chemistry, Duke University, Durham, NC, USA
Janet R. Sparrow Department of Ophthalmology, Columbia University, New York, NY, USA
Parameswaran G. Sreekumar Arnold and Mabel Beckman Macular Research Center, Doheny Eye Institute, University of Southern California, Los Angeles, CA, USA
xvi |
Contributors |
Paul Sternberg Jr. Vanderbilt Eye Institute, Vanderbilt University, Nashville, TN, USA
Robert D. Stratton Department of Ophthalmology, University of Florida, Gainesville, FL, USA
Division of Small Animal Clinical Sciences, School of Veterinary Medicine, University of Florida, Gainesville, FL, USA
Kazushi Tamai Department of Ophthalmology and Visual Science, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan
Debra A. Thompson Departments of Ophthalmology and Visual Sciences, and Biological Chemistry, University of Michigan Medical School,
Ann Arbor, MI, USA
Joshua M. Thurman Department of Medicine, University of Colorado Denver School of Medicine, Denver, CO, USA
Kazuyuki Tomida Department of Ophthalmology and Visual Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
Jingsheng Tuo Laboratory of Immunology, National Eye Institute, Bethesda, MD, USA
Amrisha Verma Department of Ophthalmology, University of Florida, College of Medicine, Gainesville, FL, USA
Ivan Vrcek Department of Ophthalmology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA
Hao Wang Department of Ophthalmology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA
Man Yu Department of Ophthalmology, Oklahoma City, OK, USA
McGee Eye Institute, Oklahoma City, OK, USA
Ophthalmic Laboratories and Department of Ophthalmology,
West China Hospital, Sichuan University, Chengdu, Sichuan, China
Marco A. Zarbin Institute of Ophthalmology and Visual Science,
University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, NJ, USA
Biren Zhao Department of Ophthalmology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA
Chapter 1
Review of Emerging Treatments
for Age-Related Macular Degeneration
Marco A. Zarbin and Philip J. Rosenfeld
Abstract In the era of pathway-based therapy, all treatments for AMD will address some step in the pathway that leads from early to late AMD. Steps in AMD pathogenesis that appear to be good targets for drug development include the following:
(1) oxidative damage, (2) lipofuscin accumulation, (3) chronic inßammation, (4) mutations in the complement pathway, (5) mitochondrial damage, (6) Alu RNA accumulation in RPE, and (7) BMP-4 accumulation in RPE. Steps in neovascularization that can be targeted for drug development and combination therapy include the following: (1) angiogenic factor production, (2) extracellular factor release, (3) binding of factors to extracellular receptors (and activation of intracellular signaling after receptor binding), (4) endothelial cell activation (and basement membrane degradation), (5) endothelial cell proliferation, (6) directed endothelial cell migration, (7) extracellular matrix remodeling, (8) tube formation, and (9) vascular stabilization. Combination therapy will likely supplant monotherapy as the treatment of choice because the clinical beneÞts will likely be superior in preventing the complications of AMD.
M.A. Zarbin (*)
Institute of Ophthalmology and Visual Science, University of Medicine
and Dentistry of New Jersey, New Jersey Medical School, Doctors OfÞce Center, 90 Bergen Street, Newark, NJ 07103, USA
e-mail: zarbin@umdnj.edu
P.J. Rosenfeld
Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA
R.D. Stratton et al. (eds.), Studies on Retinal and Choroidal Disorders, Oxidative Stress |
1 |
in Applied Basic Research and Clinical Practice, DOI 10.1007/978-1-61779-606-7_1, © Springer Science+Business Media, LLC 2012
